Nov 7, 2022

7 November 2022 Transforming the process of prostate cancer diagnosis - this month will see the launch of a revolutionary device that is set to transform the process of prostate cancer diagnosis. The Cambridge Prostate Biopsy Device (CamPROBE) is designed to reduce the risk of infection, compared with traditional transrectal biopsies, and improve the experience for patients. The cost is also expected to be less than half that of existing devices. With one in eight men diagnosed with prostate cancer, urology expert Prof Vincent Gnanapragasam and his team at the University of Cambridge and Cambridge University Hospitals NHS Trust devised the CamPROBE with the aim of making prostate biopsy simple, safe and affordable. Traditionally, prostate cancer has been diagnosed with a transrectal needle biopsy of the prostate, guided by an ultrasound probe inserted into the rectum. This approach carries a significant risk of side effects, including urinary infections and severe sepsis, as the needle traverses the rectal wall a number of times on the way to the prostate. As a result, medical and professional bodies now advocate using the transperineal route (the space between the legs and under the scrotum) instead. The CamPROBE is designed to be a cost-effective, simple way of accessing the prostate via the transperineal route in an outpatient setting. Unlike existing biopsy devices, it requires only two incisions instead of the typical 12. And it incorporates a needle to deliver local anaesthetic—sheathed within a coaxial cannula for ease of use. Cambridge Enterprise worked with healthcare innovation consultancy  Health Tech Enterprise  to secure intellectual property protection for the CamPROBE device. They also helped with the procurement of grant funding from the National Institute for Health and Care Research (NIHR) to enable the CamPROBE device to be refined, clinically evaluated and, ultimately, commercialised. The CamPROBE inventors worked with product development company  JEB Technologies  to secure CE marking for the device. Cambridge Enterprise has now signed a  licensing  agreement for CamPROBE with JEB Technologies. JEB Technologies is launching CamPROBE at MEDICA 2022 in Düsseldorf, Germany, on 14-17 November. There will be a demonstration of the device on stand H52 in hall 16. CamPROBE was supported by the National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre (BRC-1215-20014) and NIHR Cambridge Clinical Research Facility and funded by the NIHR i4i (Invention for Innovation) product development award. Read full article:  https://www.enterprise.cam.ac.uk/news/cambridge-enterprise-licences-unique-new-device-for-cancer-diagnosis/